Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$116.80 USD

116.80
5,256,080

-0.93 (-0.79%)

Updated Nov 6, 2024 04:02 PM ET

After-Market: $116.78 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks News

Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y

Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.

    Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View

    Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.

      GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down

      GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.

        Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag

        Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.

          Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up

          Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.

            McKesson (MCK) Beats Earnings & Revenue Estimates in Q2

            McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.

              Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

              Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up

                On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.

                  LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance

                  Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.

                    Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View

                    Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.

                      Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up

                      Baxter (BAX) exited the third quarter on a solid note, courtesy of stellar performances by the company's hospital products and renal segments.

                        NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut

                        NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.

                          Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates

                          Accuray (ARAY) rides high on its product and service segments in Q1.

                            Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance

                            Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.

                              Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues

                              Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.

                                Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact

                                Edwards Lifesciences (EW) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from recent natural disasters in the Caribbean and the United States.

                                  Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y

                                  Anthem's (ANTM) strong third-quarter results were driven by solid enrollment growth.

                                    PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up

                                    The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.

                                      Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View

                                      Centene's (CNC) strong third-quarter earnings were driven by solid revenue growth.

                                        Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

                                        We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.

                                          Baxter International (BAX) Q3 Earnings: What's in Store?

                                          Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.

                                            Quest Diagnostics (DGX) Beats Earnings in Q3, Updates View

                                            Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.

                                              Company News For Oct 19, 2017

                                              Companies in the News are: FOGO,ABT,AGN,EA

                                                Varian Medical (VAR) Initiates Halcyon Treatment in Europe

                                                Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.

                                                  Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed

                                                  Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.